FDA Approves New Epinephrine Injection

The US Food and Drug Administration has approved Symjepi for the emergency treatment of severe allergic reactions, including anaphylaxis.
____________________________________________________________________________________________________________________________
RELATED CONTENT
Are Expired EpiPens Still Effective?
Omalizumab May Prevent Allergic Responses Earlier Than Previously Thought
____________________________________________________________________________________________________________________________

Symjepi contains 2 prefilled syringes with a single dose of 0.3 mg of epinephrine (adrenaline) administered immediately to treat acute anaphylactic reactions. Patients who experience allergic reactions to insect bites or stings, foods, drugs, other allergens or have idiopathic or exercise-induced anaphylaxis can be prescribed the new drug.

—Melissa Weiss

Reference:

Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe [press release]. San Diego, CA: Adamis; June 15, 2017. http://ir.adamispharmaceuticals.com/phoenix.zhtml?c=99350&p=irol-newsArticle&ID=2281259. Accessed June 16, 2017.